Literature DB >> 19155425

Differences between dietary supplement and prescription drug omega-3 fatty acid formulations: a legislative and regulatory perspective.

Nancy Collins1, Ann P Tighe, Stephen A Brunton, Penny M Kris-Etherton.   

Abstract

The medical management of many diseases and conditions can include either restriction or provision of specific essential nutrients. When such nutrients are needed, there are often both prescription and nonprescription products available, as in the case of nicotinic acid or omega-3 fatty acids. Although they may seem to contain similar ingredients, there may be important differences between the prescription and dietary-supplement preparations. The manufacturing of prescription pharmaceutical products is regulated by the US Food and Drug Administration (FDA), which mandates standards for consistency and quality assurance. Dietary supplements are available to consumers under the provisions of the Dietary Supplement Health and Education Act of 1994, for which the FDA has the burden of proving a dietary supplement is harmful rather than requiring the manufacturer prove that the supplement is safe. Consumers and medical professionals should be aware of the important qualitative and quantitative differences between the FDA-approved prescription formulations and dietary supplements, particularly when an essential nutrient is part of the medical management of a disease or condition.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19155425     DOI: 10.1080/07315724.2008.10719743

Source DB:  PubMed          Journal:  J Am Coll Nutr        ISSN: 0731-5724            Impact factor:   3.169


  9 in total

1.  A Comparative Overview of Prescription Omega-3 Fatty Acid Products.

Authors:  Matthew K Ito
Journal:  P T       Date:  2015-12

2.  Overview of omega-3 Fatty Acid therapies.

Authors:  J Chris Bradberry; Daniel E Hilleman
Journal:  P T       Date:  2013-11

Review 3.  Plants vs. cancer: a review on natural phytochemicals in preventing and treating cancers and their druggability.

Authors:  Hu Wang; Tin Oo Khor; Limin Shu; Zheng-Yuan Su; Francisco Fuentes; Jong-Hun Lee; Ah-Ng Tony Kong
Journal:  Anticancer Agents Med Chem       Date:  2012-12       Impact factor: 2.505

4.  An examination of marketing techniques used to promote children's vitamins in parenting magazines.

Authors:  Corey Hannah Basch; Katherine J Roberts; Danna Ethan; Sandra Samayoa-Kozlowsky
Journal:  Glob J Health Sci       Date:  2014-11-26

Review 5.  Use and abuse of dietary supplements in persons with diabetes.

Authors:  Bridget A Hannon; William D Fairfield; Bryan Adams; Theodore Kyle; Mason Crow; Diana M Thomas
Journal:  Nutr Diabetes       Date:  2020-04-27       Impact factor: 5.097

6.  Monoacylglycerol Form of Omega-3s Improves Its Bioavailability in Humans Compared to Other Forms.

Authors:  Bernard Cuenoud; Isabelle Rochat; Maria Laura Gosoniu; Lenaick Dupuis; Evan Berk; Anke Jaudszus; Jochen G Mainz; Gaudenz Hafen; Maurice Beaumont; Cristina Cruz-Hernandez
Journal:  Nutrients       Date:  2020-04-07       Impact factor: 5.717

Review 7.  Critical Differences Between Dietary Supplement and Prescription Omega-3 Fatty Acids: A Narrative Review.

Authors:  Daniel E Hilleman; Barbara S Wiggins; Michael B Bottorff
Journal:  Adv Ther       Date:  2020-01-09       Impact factor: 3.845

8.  Potential benefits of icosapent ethyl on the lipid profile: case studies.

Authors:  Daniel E Hilleman; Mark A Malesker
Journal:  Clin Med Insights Cardiol       Date:  2014-02-02

Review 9.  Prescription omega-3 fatty acid products: considerations for patients with diabetes mellitus.

Authors:  Nadeem Tajuddin; Ali Shaikh; Amir Hassan
Journal:  Diabetes Metab Syndr Obes       Date:  2016-04-19       Impact factor: 3.168

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.